Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.750
0.00 (0.00%)
At close: Apr 1, 2025, 4:00 PM
1.730
-0.020 (-1.13%)
After-hours: Apr 1, 2025, 4:40 PM EDT

Regulus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Revenue
----10.01
Upgrade
Revenue Growth (YoY)
----46.46%
Upgrade
Cost of Revenue
35.3721.1518.4117.7915.35
Upgrade
Gross Profit
-35.37-21.15-18.41-17.79-5.34
Upgrade
Selling, General & Admin
14.679.969.8310.028.81
Upgrade
Operating Expenses
14.679.969.8310.028.81
Upgrade
Operating Income
-50.04-31.11-28.24-27.82-14.16
Upgrade
Interest Expense
-0.16-0.6-0.69-0.86-1.81
Upgrade
Interest & Investment Income
3.841.680.610.20.23
Upgrade
EBT Excluding Unusual Items
-46.36-30.04-28.32-28.47-15.73
Upgrade
Other Unusual Items
---0.66-
Upgrade
Pretax Income
-46.36-30.04-28.32-27.81-15.73
Upgrade
Income Tax Expense
0000-
Upgrade
Net Income
-46.36-30.04-28.32-27.81-15.73
Upgrade
Net Income to Common
-46.36-30.04-28.32-27.81-15.73
Upgrade
Shares Outstanding (Basic)
56191593
Upgrade
Shares Outstanding (Diluted)
56191593
Upgrade
Shares Change (YoY)
197.18%24.25%78.07%145.01%102.65%
Upgrade
EPS (Basic)
-0.82-1.58-1.86-3.24-4.50
Upgrade
EPS (Diluted)
-0.82-1.58-1.86-3.24-4.50
Upgrade
Free Cash Flow
-42.01-27.38-25.89-24.38-12.54
Upgrade
Free Cash Flow Per Share
-0.75-1.44-1.70-2.85-3.58
Upgrade
Gross Margin
-----53.38%
Upgrade
Operating Margin
-----141.47%
Upgrade
Profit Margin
-----157.21%
Upgrade
Free Cash Flow Margin
-----125.28%
Upgrade
EBITDA
-49.69-30.88-28.12-27.36-13.69
Upgrade
EBITDA Margin
-----136.80%
Upgrade
D&A For EBITDA
0.350.230.120.460.47
Upgrade
EBIT
-50.04-31.11-28.24-27.82-14.16
Upgrade
EBIT Margin
-----141.47%
Upgrade
Revenue as Reported
----10.01
Upgrade
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q